This article is maintained by: Elsevier
Article Title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(21)00234-8
CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(21)00191-4
Content Type: article
Copyright: © 2021 Elsevier Ltd. All rights reserved.